<DOC>
	<DOCNO>NCT02418390</DOCNO>
	<brief_summary>The aim study investigate efficacy safety prophylactic central lymph node dissection papillary thyroid carcinoma .</brief_summary>
	<brief_title>The Efficacy Safety Prophylactic Central Lymph Node Dissection Papillary Thyroid Carcinoma</brief_title>
	<detailed_description>The aim study investigate efficacy safety prophylactic central lymph node dissection papillary thyroid carcinoma . Primary outcome structural recurrence rate . Secondary outcomes operative time , postoperative complication , quality life . The enrolled patient randomly assign control group intervention group ( 1:1 allocation ) .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>clinical radiological evidence lymph node metastasis evidence hyperparathyroidism pregnant woman uncontrolled diabetes , hypertension , chronic renal failure aspirin anticoagulant medication within 7 day clinical trial participation within 30 day radiation exposure head neck previous operation neck advance thyroid cancer include adjacent organ invasion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>